Fibrin Or Fibrin Intermediates, E.g., Fibrinogen, Etc. Patents (Class 530/382)
  • Patent number: 10188965
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasm
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: January 29, 2019
    Assignee: CSL BEHRING GMBH
    Inventors: Hung Pham, Jeffrey Michael Hey, Darren Nguy
  • Patent number: 9938501
    Abstract: A therapeutic composition comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in a three-dimensional biocompatible gel matrix, and methods, and systems for preparing and using encapsulated adipose-derived mesenchymal stem cells. Hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The gel matrix allows the release of cellular factors from the encapsulated stem cells to surrounding tissues to achieve desired therapeutic results.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: April 10, 2018
    Assignee: JointechLabs, Inc.
    Inventors: Nathan Katz, Felix Pustilnik
  • Patent number: 9775884
    Abstract: A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: October 3, 2017
    Assignee: The Chemo-Sero-Therapeutic Research Institute
    Inventors: Shinichi Miyagawa, Tatsuya Araki, Tsutomu Hamuro, Mika Okuda, Hiroshi Kaetsu
  • Patent number: 9598461
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 21, 2017
    Assignee: CSL Behring GmbH
    Inventors: Hung Pham, Jeffrey Michael Hey, Darren Nguy
  • Patent number: 9447171
    Abstract: A process for purification of a fragment antibody from a culture medium also comprising at least one impurity is provided. The purification is carried out after the pH of the culture medium has been reduced to a pH at which the fragment antibody is soluble, but one or more of the impurities are insoluble. A process for the preparation of a fragment antibody employing such a purification process is also provided.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 20, 2016
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventor: John Macdonald Liddell
  • Patent number: 9422361
    Abstract: There is described a chromatographic purification process that allows highly purified von Willebrand factor (vWF) and Fibronectin (Fn) to be obtained, starting from a biological fraction enriched in vWF and Fn and easily scaled up to industrial level. Chromatographic purification was obtained by a strong anionic exchange resin. The concentrates obtained have a high specific activity and, given the low content of contaminant proteins, are particularly suitable for therapeutic use.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: August 23, 2016
    Assignee: KEDRION S.P.A.
    Inventors: Filippo Mori, Ilaria Nardini, Claudio Farina, Claudia Nardini
  • Patent number: 9243239
    Abstract: This invention provides chromatographic methods for the purification of a cystathionine ?-Synthase (CBS) protein, particularly truncated variants thereof and compositions and pharmaceutical compositions prepared therefrom.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 26, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Richard Carrillo, Jan P. Kraus, Tomas Majtan, David Naveh
  • Patent number: 9138406
    Abstract: The invention relates to a gel composition comprising: a) a carboxy polymethylene polymer; b) glycine; c) a source of calcium ions; and d) water. The invention also extends to a dry composition comprising the aforementioned components a), b) and c). The gel compositions of the invention are useful for the prophylaxis and treatment of epistaxis. The gel compositions can be easily administered to the nasal cavity and do not require removal after use.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: September 22, 2015
    Assignee: PHARMACURE HEALTH CARE AB
    Inventor: Björn Petruson
  • Patent number: 9028801
    Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 12, 2015
    Assignees: Electrophoretics Limited, Medical Research Council, University College London
    Inventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
  • Patent number: 9012393
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: April 21, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • Publication number: 20150045539
    Abstract: A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterised in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 12, 2015
    Inventors: Petra Schulz, Werner Ghringer, Friedrich Schön, Caroline Leitinger, Jürgen Römisch, Rainer Pape
  • Patent number: 8921317
    Abstract: A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen ? and chains and the ? chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO2 canister or a shaker jet.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: December 30, 2014
    Assignee: BAE Systems Information and Electronic Systems Integration Inc.
    Inventor: Robert A. Burton
  • Patent number: 8906856
    Abstract: ClotGel is a single-component hemostatic agent designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its crosslinking technology generates an adhesive stable fibrin clot using a single component (fibrin II) required for hemostasis. The agent is a mixture of lyophilized polymerized fibrin II and fibrin II monomer which is polymerized and stabilized when in contact with the blood. The attachment properties of the gel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed within 1 minute of application.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: December 9, 2014
    Assignee: Biomedica Mangement Corporation
    Inventors: George David Falus, Leonid Medved
  • Publication number: 20140343253
    Abstract: There is a recognized need for novel, more simplified, approaches to isolation of plasma from whole blood, as well as a need to isolate cell-free plasma fractions containing different plasma proteins. Methods are divulged for use of aqueous phase systems, formed in blood or blood containing solutions via addition of a single polymer at relatively low concentration, to effect isolation (clarification) of plasma proteins from blood cells. Methods are also divulged to replace widely used Cohn-type plasma protein fractionation which is based on sequential addition of up to 40% (v/v) ethanol and other precipitants, with simple sequential addition of a polyacid. The latter results in isolation of plasma protein fractions (i.e. fibrinogen, immunoglobulin, albumin) in sequence similar to that obtained with Cohn Fractionation and therefore may be suitable for use to reduce solvent use and solvent-related process complications in existing plasma protein purification processes.
    Type: Application
    Filed: September 14, 2012
    Publication date: November 20, 2014
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: James Van Alstine, Mikael Berg, Johanna Kjorning, JAMIL Shanagar
  • Patent number: 8877195
    Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 4, 2014
    Assignee: The Regents of the University of California
    Inventor: Katerina Akassoglou
  • Patent number: 8865868
    Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
  • Patent number: 8865869
    Abstract: Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: October 21, 2014
    Assignee: Worcester Polytechnic Institute
    Inventors: Kevin G. Cornwell, George D. Pins, Kristen Billiar
  • Publication number: 20140273153
    Abstract: The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) a biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of the disclosed methods.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Mosaic Biosciences, Inc.
    Inventors: Alexei KAZANTSEV, Peter D. MARINER, Martin STANTON
  • Patent number: 8828436
    Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: September 9, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
  • Publication number: 20140248643
    Abstract: A chromatographic process for the enrichment of at least one compound of interest from a mixture is proposed, using chromatographic columns, wherein said process involves a sequence of the following steps: (i) a cyclic accumulation phase, in which the chromatographic columns are alternatingly operated in an interconnected phase, followed by a disconnected phase, wherein subsequently columns exchange places and wherein the phases are carried out sequentially; (ii) a cyclic separation phase, in which the chromatographic columns are alternatingly operated in an interconnected phase, followed by a disconnected phase, wherein after these phases columns exchange places to undergo the next interconnected and disconnected phases; and (iii) an elution phase, in which from the column, which at the end of phase (i) or at the end of phase (ii) contains the compound of interest, is extracted via the outlet.
    Type: Application
    Filed: January 29, 2014
    Publication date: September 4, 2014
    Applicant: CHROMACON AG
    Inventors: Thomas MÜLLER-SPÄTH, Guido STRÖHLEIN, Lars AUMANN, Michael BAVAND, Nicole ULMER
  • Publication number: 20140227766
    Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
    Type: Application
    Filed: June 1, 2012
    Publication date: August 14, 2014
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Stanley Gagnon
  • Patent number: 8753670
    Abstract: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: June 17, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Yves A. Delmotte
  • Publication number: 20140154233
    Abstract: The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or Factor VIII and/or von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising fibrinogen and/or Factor VIII and/or VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or Factor VIII and/or VWF which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 5, 2014
    Applicant: CSL LIMITED
    Inventors: Hung PHAM, Jeffrey Michael HEY, Darren NGUY
  • Patent number: 8741845
    Abstract: ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or as non-invasive sealant. Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis. The attachment properties of the cake as well as the rapid formation of and stability of the fibrin clot ensures that a strong stable fibrin clot is formed within 1 to 5 minutes depending on the grade of the wound. The agent is safe, biocompatible, biodegradable and can be stored at room temperature for one year.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 3, 2014
    Assignee: Biomedica Mangement Corporation
    Inventors: George David Falus, Leonid Medved
  • Publication number: 20140148580
    Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins.
    Type: Application
    Filed: October 17, 2013
    Publication date: May 29, 2014
    Applicant: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Michel NOGRE, Pierre PORTE, Michel TELLIER
  • Publication number: 20140141488
    Abstract: Sequence of 55 New Found Proteins—2 new proteins in Cryoprecipitate—8 new proteins in Fraction III—8 new proteins in Prothrombin Complex Concentrate—2 new found proteins in AFCC (Fraction 33)—3 new proteins in Fraction IV and 4 new found proteins in AFOD (Fraction 42)—2 in HemoRAAS®, 3 in FibroRAAS®, 5 in GammaRAAS®, 3 in AFCC®, 1 in Fraction 3-2, 2 in Fraction 3, 4 in FibingluRAAS® (Thrombin), 3 in AFOD®, 1 in AlbuRAAS®, 1 in FibingluRAAS® (High concentrate Fibrinogen), 1 in AFCC® (From fraction IV), 2 in Transferrin from Human Plasma and their name KH1 through KH55, and 16 existing proteins in which good KH healthy cells exists and their application.
    Type: Application
    Filed: January 31, 2013
    Publication date: May 22, 2014
    Inventor: Kieu Hoang
  • Patent number: 8686225
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 1, 2014
    Assignee: Ventria Bioscience Inc.
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Publication number: 20140087441
    Abstract: The invention discloses a novel application of fibrinogen-420 and its active domain (alpha EC domain), and a separate alpha EC domain protein has the same or similar function with fibrinogen-420. Fibrinogen-420 and its active domain can be widely used in inhibiting protein aggregation, helping protein refolding, drugs which can prevent and/or treat protein conformation disease, detecting denatured protein in quality control and protect protein from denaturation.
    Type: Application
    Filed: September 6, 2013
    Publication date: March 27, 2014
    Applicant: Tsinghua University
    Inventors: YONGZHANG LUO, Huadong Tang, Yan Fu
  • Publication number: 20140038892
    Abstract: Conjugates of hydrophilic carboxy polysaccharides with protein members of the fibroblast growth factor (FGF) family and variants thereof. The conjugates provide a modified bioactivity and stability of FGFs for various therapeutic applications.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Inventors: Avner Yayon, Roy Sirkis, Boaz Amit, Avraham Wortzel
  • Publication number: 20140011978
    Abstract: Heparin binding peptides derived from a Tenascin (TNC) III1-5 domain or a fibrinogen ?15-66 domain have been found that bind certain cytokines with high affinity. Materials and methods for making compositions and devices using these peptides are disclosed.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 9, 2014
    Applicant: EPFL-TTO
    Inventors: Jeffrey A. Hubbell, Mikaël Martino, Laura De Laporte, Jeffrey J. Rice, Federico Tortelli
  • Publication number: 20130345401
    Abstract: Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A?, B? and ? chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.
    Type: Application
    Filed: March 2, 2012
    Publication date: December 26, 2013
    Applicant: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.
    Inventors: Satoshi Sekiguchi, Manabu Takahisa, Masahiro Tomita
  • Publication number: 20130345321
    Abstract: The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. The gel further contains proteins from the extracellular matrix that promote cell growth and density in and around the gel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Inventors: James C. Iatridis, Clare Canal Guterl
  • Publication number: 20130337479
    Abstract: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 19, 2013
    Applicant: MCBI INC.
    Inventors: Kazuhiko Uchida, Kohji Meno, Hideaki Suzuki
  • Patent number: 8598319
    Abstract: The invention is related to a process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing freeze-dried concentrates of said proteins comprising the steps of: chromatographic purification comprising the steps of loading an anion exchanger of weak base type with the said solubilized fraction, previously equilibrated with a buffer of a predetermined ionic strength of an alkaline pH, which allows to retain the biological glue, elution of the biological glue by increasing the ionic strength of the said buffer, and separation of FXIII from fibrinogen by addition to at least one part of the biological glue eluate of at least one chemical agent precipitating the FXIII, and recovery of the resulting purified fibrinogen containing supernatant solution, and diafiltration of the fibrinogen, biological glue and resolubilized FXIII solutions, followed by a freeze-drying of said solutions.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: December 3, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Nogré Michel, Porte Pierre, Tellier Michel
  • Patent number: 8575101
    Abstract: Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or trigger healing of bone fractures which otherwise would not heal. The matrices are biocompatible, preferably biodegradable, and can be formed in vitro or in vivo, at the time of implantation. The PTH may be a part of a fusion peptide. PTH can be incorporated into the matrices with full retention of its bioactivity. PTH can be releasably incorporated in the matrix.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: November 5, 2013
    Assignee: Kuros Biosurgery AG
    Inventors: Jason Schense, John Watson, Isabelle Arrighi
  • Publication number: 20130287744
    Abstract: In general, the present invention is related to biopolymer and biocomposite materials and structures, and methods of making and using the same. In some embodiments, the present invention is directed to oriented collagen based biocomposite materials and structures, and methods of making.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Applicant: Fibralign Corporation
    Inventors: Mikhail Vitoldovich Paukshto, David Harwood McMurtry, George R. Martin, Tatiana Zaitseva
  • Publication number: 20130274444
    Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
    Type: Application
    Filed: September 20, 2011
    Publication date: October 17, 2013
    Applicant: OCTAPHARMA AG
    Inventors: Petra Schulz, Rainer Pape, Werner Gehringer
  • Patent number: 8557535
    Abstract: A method of preparing a fibrinogen rich composition is disclosed. One embodiment of the method involves contacting plasma with a hydrogel capable of increasing in mass upon contact with said plasma; maintaining said contact for a period of time sufficient for said hydrogel to absorb a substantial amount of at least the water from said plasma to produce a swollen hydrogel and a fibrinogen rich phase; and separating said fibrinogen rich phase from said swollen hydrogel; whereby said fibrinogen rich composition is produced.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: October 15, 2013
    Assignee: Incept LLC
    Inventor: Chandrashekhar P. Pathak
  • Patent number: 8557773
    Abstract: The invention provides low-half life fibrinogen with reduced sialyation as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: October 15, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
  • Patent number: 8551994
    Abstract: For the separation, removal, isolation, purification, characterization, identification or quantification of fibrinogen or a protein that is a fibrinogen analogue, an affinity adsorbent is used that is a compound of formula II wherein one X is N and the other is N, C—Cl or C—CN; Y is O, S or NR2; 0 Z is O, S or NR3; R2 and R3 are each H, alkyl, hydroxyalkyl, benzyl or &bgr; -phenylethyl; n is 0 to 6; A is a support matrix, optionally linked to the triazine ring by a spacer; R7 is a group bearing a positive charge at neutral pH; W is an optional linker; V is an aromatic group; and R8 and R9 are each H, OH, alkyl, alkoxy, amino, NH2, acyloxy, acylamino, CO2H, sulphonic acid, carbamoyl, sulphamoyl, alkylsulphonyl or halogen or a cyclic structure such as a morpholino group, or R8 and R9 are linked to form such a cyclic structure.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: October 8, 2013
    Assignee: Prometic Biosciences Ltd
    Inventors: Jason Richard Betley, James Christopher Pearson, Ben Martin Beacom, Tadeusz Antoni Podgorski, Robert William Pannell
  • Patent number: 8513380
    Abstract: Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: August 20, 2013
    Assignee: Georgia Tech Research Corporation
    Inventor: Thomas Harrison Barker
  • Patent number: 8512740
    Abstract: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, will rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing. A fibrin foam may be made by injecting fibrinogen foam into a clotting protein, such as thrombin.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: August 20, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Yves A. Delmotte
  • Publication number: 20130202675
    Abstract: Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.
    Type: Application
    Filed: October 4, 2012
    Publication date: August 8, 2013
    Applicant: Dynasil Biomedical Corporation
    Inventor: Dynasil Biomedical Corporation
  • Publication number: 20130183737
    Abstract: The invention is based on the surprising finding that proteins regulated by excessive EGFR signalling in the liver may be used as biomarkers in the diagnosis, prognosis and/or monitoring of treatment of diseases, including liver cell dysplasia or hepatocellular carcinoma (HCC), wherein the protein is selected from a first group consisting of Arginase type II, 4931406C07Rik (Ester hydrolase C11orf54 homolog), Akr1c12 protein, Alanyl-tRNA synthetase, Aldo-keto reductase family 1 member C14, Aldo-keto reductase family 1 member C6, Aldolase 3, Alpha glucosidase 2, Beta 5-tubulin, Cai protein (Pdia4), cDNA sequence BC021917 (dihydroxyacetone kinase 2 homolog), Farnesyl diphosphate synthetase, Fatty acid binding protein 5 epidermal, Inosine triphosphatase, Interleukin 25, Kininogen 1, LIM and SH3 protein 1, Major vault protein, Nucb1 protein, Poly(rC) binding protein 2; heterogeneous nuclear ribonucleoprotein X, Psmd11 protein, RIKEN cDNA 2410004H02, Rps12 protein, Sars1 protein, Sorcin, T43799 proteasome protein p
    Type: Application
    Filed: June 23, 2011
    Publication date: July 18, 2013
    Applicant: MODPRO AB
    Inventor: Jurgen Borlak
  • Publication number: 20130164827
    Abstract: The present invention provides methods for separating proteins from a protein mixture. In one aspect, a method for separating a high concentration protein mixture into a bound protein fraction and a flow-through protein fraction can include delivering a protein mixture through an ion exchange column at a fixed pH and a fixed salt concentration. The fixed pH and the fixed salt concentration have been preselected to cause separation of the protein mixture into a bound protein fraction and a flow-through protein fraction. In this case, the bound protein fraction binds to the ion exchange column and the flow-though protein fraction flows though the ion exchange column. The method can further include receiving the flow-through protein fraction from the ion exchange column separate from the bound protein fraction, wherein either the bound protein fraction or the flow-through fraction contains a protein of interest.
    Type: Application
    Filed: November 5, 2012
    Publication date: June 27, 2013
    Inventor: Anthony R. Torres
  • Patent number: 8465772
    Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: June 18, 2013
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
  • Patent number: 8465773
    Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: June 18, 2013
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
  • Publication number: 20130149740
    Abstract: The invention discloses a method for the production of a polymerized product comprising the following steps: providing a polymerization device to which a polymerization mixture and a separation medium can be applied and wherein flow of said mixture and medium can be conducted in appropriate ducts for said mixture and medium, transporting said polymerization mixture in a duct of said polymerization device thereby allowing the polymerization reaction, transporting said mixture in a duct of said polymerization device in a continuous flow, interrupting said continuous flow of said mixture with said separation medium so as to obtain consecutive volumes of said mixture and volumes of said separation medium, further transporting said consecutive volumes of said mixture and volumes of said separation medium in a duct of said polymerization device wherein said mixture further polymerizes to obtain a discontinuous polymerized product, and removing said discontinuous polymerized product from said polymerization devi
    Type: Application
    Filed: June 14, 2012
    Publication date: June 13, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Yves Delmotte
  • Patent number: 8461302
    Abstract: The present invention provides improved methods for the purification of factor XIII. In particular, the methods provide compositions containing 5% or less contaminating proteins. In particular embodiments of the present invention the methods provide purified factor XIII compositions comprising less than 1% activated factor XIII, less than 2% protein aggregates, and/or less than 5% charge isomers of factor XIII. The methods do not require the use a precipitation or crystallization step common to prior methods of isolating factor XIII. Instead, the method uses immobilized metal affinity chromatography to remove various contaminants common to recombinant expression of factor XIII. Further, a combination of various chromatography methods including ion exchange chromatography, hydrophobic affinity chromatography, and immobilized metal affinity chromatography comprise a simple and less expensive method to produce a pharmaceutical grade factor XIII product at high yield.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: June 11, 2013
    Assignee: Zymogenetics, Inc.
    Inventors: Carol Jewell, Hardarshan Cheema, Deborah Hogg, Wenmao Meng, Ray O'Donnell, Ewan Robertson, Andrew Topping
  • Publication number: 20130144039
    Abstract: An objective of the invention is to provide an adsorbent allowing purification of a blood coagulation factor or a cell adhesion factor under mild conditions, according to simple procedures, and at a low cost and safely while having a high affinity and a high resistance to deterioration, and a method for purifying the blood coagulation factor or the cell adhesion factor; a solution is to apply a polypeptide having peptide fragments represented by formula (1) as the adsorbent for the blood coagulation factor or the cell adhesion factor, and to purify the blood coagulation factor or the cell adhesion factor using the adsorbent: -(Pro-Hyp-Gly)n- Wherein, in formula (1), n is an integer from 2 to 9,000.
    Type: Application
    Filed: December 5, 2012
    Publication date: June 6, 2013
    Applicant: JNC CORPORATION
    Inventor: JNC Corporation